Interestingly, KRAS mutation, known to be an adverse predictive and prognostic marker in mCRC patients treated with EGFR inhibitors, is less frequent in rectal cancer and does not convey the same predictive information [76, 77]. This evidence concerns the gene EGFR and rectal cancer.